Compier L2A Case Management

Home / Innovation / Compier L2A Case Management

Automate EMA E2B R3 File filter process for improved efficiency and compliance

Pharma companies are required to download E2B R3 files from the EV Web portal based on active substances (not based on the company’s products). Due to this regulatory change, Pharmacovigilance operations at small to mid-size companies are challenged with timely completion of review and submission of huge volumes of ICSRs.  It is must for companies to include these ICSRs in the company’s centralized safety database to comply with other regulatory agencies for expedited reporting.

Compier L2A Case Management

Compier L2A Case Management is an E2B R3 File Filter to help companies automate the filtering process and designed specifically to address the efficiency and case volume management related to L2A cases. L2A Case Filter automatically reads the product information from the incoming E2B R3 files and compare it with existing configurations. Compier L2A Case Management module has the capability to compare configurations defined in the drug safety system or with a custom defined list and filter out any files which are not related to the pharma company products. This module is highly configurable and provides a comprehensive activity log for future reference.

Office Desk

Key Product Features

L2A Case Filter provides various, ready to use dashboards and reports to manage the process efficiently.

  • Dashboard for total cases processed in a specific time interval with details of success and non-success numbers
  • Total number of cases received for a country and processed based on report type
  • Multiple trend reports indicating total number of cases reported by time interval, source, product etc

Compier L2A Case Filter directly reduces manual effort and address the regulatory compliance needs of the pharmacovigilance department.

How Do we Deliver

Compier L2A Case Management is a component of our Compier platform. It can be deployed on its own or in combination with other modules of the platform.

New Insights

4 Effective Strategies to Accelerate Site Selection to Activation

Introduction to the site selection process Clinical research organizations (CRO) predominantly rely on the internal networks and investigator database to support a clinical study for a drug. As the clinical sphere continues to expand at a rapid pace, there is an upsurge in demand for clinical trial sites worldwide. CROs are striving for new sites […]

Aggregate Reporting – Significance, Classification and Challenges

Aggregate reports are the cumulative reports in the database that emphasise on evaluation of safety profile and risk-benefit analysis of a drug. Aggregate reporting is the process of compilation and submission of aggregate reports to the regulatory agencies over the period of the product’s life cycle (during pre-marketing and post-marketing phase) to provide a comprehensive [...]

Literature Screening – Process overview, challenges en-route and the scope for automation

Medical and scientific literature is a valuable source of safety information that helps in monitoring benefit-risk profiles and emerging safety issues of medicinal products. Literature screening is conducted to ascertain abstracts and articles that provide crucial information on serious and non-serious Individual Case Safety Reports (ICSR) reports and risk-benefit assessment of a drug. The scientific […]

Get in Touch with Us